Are you Dr. Costello?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 85 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905Phone+1 507-284-2511- Is this information wrong?
Summary
- Dr. Brian Costello, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Connecticut, and Tennessee. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2009
University of New Mexico School of MedicineResidency, Internal Medicine, 1995 - 1998
Medical College of WisconsinClass of 1995
Certifications & Licensure
MI State Medical License 2013 - 2026
MT State Medical License 2014 - 2026
WI State Medical License 2013 - 2025
FL State Medical License 2013 - 2024
AZ State Medical License 2013 - 2024
IA State Medical License 2013 - 2024
ND State Medical License 2014 - 2024- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Start of enrollment: 2009 Sep 01
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- Assessment of minimum target dose as a predictor of local failure after spine SBRT.Roman O Kowalchuk, Trey C Mullikin, Grant M Spears, Benjamin A Johnson-Tesch, Peter S Rose, Brittany L Siontis, Dong Kun Kim, Brian A Costello, Jonathan M Morris, Robe...> ;Radiotherapy and Oncology. 2024 Mar 27
- Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.Surendra Dasari, Michael R McCarthy, Antonina A Wojcik, Beth A Pitel, Arpan Samaddar, Burak Tekin, Rumeal D Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 27
- Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.Emiloju, O., Yin, J., Koubek, E., Reid, J., Borad, M., Lou, Y., Seetharam, M., Edelman, M., Sausville, E., Jiang, Y., Kaseb, A., Posey, J., Davis, S., Gores, G., Rober...> ;Investigational New Drugs. 2024 Feb 1
- Join now to see all
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Hospital Affiliations
Mayo Clinic Hospital - RochesterRochester, Minnesota
